The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Date of IPO


Market Cap


About Constellation Alpha Capital

Constellation Alpha Capital (NASDAQ: CNACU) is a blank check company, also commonly referred to as a Special Purpose Acquisition Company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

Constellation Alpha Capital Headquarter Location

Emerald View Suite 400

West Palm Beach, Florida, 33411,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Constellation Alpha Capital News

DermTech Goes Public Through Reverse Merger

Sep 5, 2019

DermTech has gained a Nasdaq listing through a reverse merger with Constellation Alpha Capital. The deal gives San Diego’s DermTech access to public investors as the company scales its scalpel-free test for skin cancer. DermTech’s skin patch captures genetic material. The company can then say whether a mole is benign or if a biopsy would be warranted, what’s billed as precision dermatology. The merger, which closed Aug. 30, provided the combined company with $29 million in capital. Investors included RTW Investments, HLM Venture Partners, and Qualcomm co-founder Irwin Jacobs. San Diego-based DermTech took over Constellation’s public stock listing – now trading as “DMTK” and “DMTKW” on Nasdaq – and the management of the business. The deal involved a one-for-two stock split. “Approximately 3.5 million pigmented lesions are assessed for melanoma each year by surgical biopsy. Our platform has the potential to greatly enhance this assessment by helping to find melanoma at earlier stages without requiring surgical incisions,” said DermTech CEO John Dobak in a statement. Dobak recently spoke at Biocom’s Devicefest and Digital Health Conference about warming up insurers and regulators to new technologies. Besides detecting skin cancer, Dermtech said it’s in the business of assessing inflammatory diseases and customizing drug treatment. The merger combined Constellation shares, proceeds from the private sale of Constellation stock and remaining Constellation cash. “The molecular diagnostics sector has meaningfully outperformed the traditional pathology sector over the last two years,” said Constellation CEO Rajiv Sarman Shukla in a statement. As another reason for supporting the merger, he cited DermTech’s flagship product, Pigmented Lesion Assay, or PLA which launched in 2016. DermTech noted a 2018 study published in Melanoma Research that found its PLA test was highly accurate and reduced unnecessary surgical procedures ten-fold. Although it recently became a public company, DermTech flirted with the idea a while back. In 2014, the company scrapped plans for a $25 million initial public offering.

Constellation Alpha Capital Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Constellation Alpha Capital Rank

  • When was Constellation Alpha Capital founded?

    Constellation Alpha Capital was founded in 2017.

  • Where is Constellation Alpha Capital's headquarters?

    Constellation Alpha Capital's headquarters is located at Emerald View, West Palm Beach.

  • What is Constellation Alpha Capital's latest funding round?

    Constellation Alpha Capital's latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.